Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 14 October 2015 | By Zachary Brennan
The US Food and Drug Administration (FDA) told RAPS' Regulatory Focus that it concurs with breast implant provider Sientra's caution in voluntarily placing a temporary hold on the US sales of all devices from Brazilian implant manufacturer Silimed.
"We concur with Sientra’s recommendations to take a cautionary approach until more is known, and we are actively working with the company and other international regulators to investigate the issue. The FDA is in close communication with the EU and Brazilian authorities as more information is gathered," FDA spokesman Eric Pahon told RAPS.
He also added that FDA "is not aware of any adverse patient events related to the current matter under investigation."
The comments come as Sientra, the largest distributor of Silimed-made implants in the US, last week told surgeons it was placing a temporary hold on the US sale of all such devices. The breast implant provider also recommended that plastic surgeons stop implanting these devices until further notice, though it stopped short of calling for surgeons to remove Silimed implants.
MHRA, Brazil Action
Sientra's caution follows the UK's Medicines and Healthcare products Regulatory Agency's (MHRA) suspension late last month of all CE certificates for Silimed medical devices after German inspectors found particle contamination in some devices made at the company's manufacturing plant in Rio.
Silimed manufactures a catalogue of more than 5,000 implants for plastic surgery, bariatric surgery (including gastric bands and balloons), urology, general surgery and other invasive silicone devices in more than 75 countries.
Following that suspension, Australia's Therapeutic Goods Administration and Brazil's National Health Surveillance Agency (Anvisa), which actually inspected the Rio facility from 28 September to 30 September, also suspended sales of the products.
Silimed Response
Silimed, meanwhile, claims that the suspensions are arbitrary as "there are no technical specifications regarding the level of particles" in Europe or elsewhere for implants.
FDA's Pahon told RAPS that there "are standards for breast implants; however, these do not include limits for particles. Manufacturers are required to have robust quality management systems that assure the quality of their products."
The company also points out that "the technical literature, the risk analysis and also the post production surveillance show that over the years the presence of sterile particles (which are not micro-organisms), is common to all medical devices, and does not reveal any risk to patients' health."
Sientra Letter to Plastic Surgeons
Tags: FDA, MHRA, ANVISA, Silimed, breast implants, particle contamination
Regulatory Focus newsletters
All the biggest regulatory news and happenings.